Matches in SemOpenAlex for { <https://semopenalex.org/work/W2318304052> ?p ?o ?g. }
Showing items 1 to 78 of
78
with 100 items per page.
- W2318304052 endingPage "106" @default.
- W2318304052 startingPage "104" @default.
- W2318304052 abstract "Crohn's disease is a chronic, or long lasting inflammatory disease in the gastrointestinal (GI) tract. Most commonly, Crohn's disease affects the small intestine and the beginning of the large intestine. Treatment for Crohn's disease usually involves drug therapy or, in certain cases, surgery. Several side effects develop from the use of drugs. A case with Crohn's disease refractory to 5-ASA, corticosteroid and azathioprine treatments who developed breast carcinoma following infliximab treatment is being presented in this report.SE, aged 44 years, presented to our polyclinic with weight loss, abdominal pain and flatulence. The patient had no response to mesalazine, steroid and azathioprine therapy. Upon identifying inflammatory stricture with abdominal MR, the medicines the patient has been using was discontinued and anti-TNF alpha (infliximab) treatment was initiated after receiving the consent of the patient. At 3rd month of treatment, the patient detected a small mass at the left breast. Mastectomy was performed and axillary lymph nodes were resected. Because breast cancer was detected following infliximab treatment in this case, we believe that a breast examination (physical examination, mammary USG) must be performed in female patients prior to infliximab therapy. How to cite this article: Goral V, Unsal B, Sivrikoz ON. A Case of Breast Cancer Following Infliximab Treatment for Treatment-Refractory Crohn's Disease. Euroasian J Hepato-Gastroenterol 2014;4(2): 104-106." @default.
- W2318304052 created "2016-06-24" @default.
- W2318304052 creator A5010731876 @default.
- W2318304052 creator A5025888459 @default.
- W2318304052 creator A5088802067 @default.
- W2318304052 date "2014-01-01" @default.
- W2318304052 modified "2023-09-26" @default.
- W2318304052 title "A Case of Breast Cancer Following Infliximab Treatment for Treatment-Refractory Crohn’s Disease" @default.
- W2318304052 cites W1979532130 @default.
- W2318304052 cites W1991973624 @default.
- W2318304052 cites W2015381243 @default.
- W2318304052 cites W2032754050 @default.
- W2318304052 cites W2042927462 @default.
- W2318304052 cites W2058820485 @default.
- W2318304052 cites W2074007950 @default.
- W2318304052 cites W2315653665 @default.
- W2318304052 doi "https://doi.org/10.5005/jp-journals-10018-1112" @default.
- W2318304052 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5913906" @default.
- W2318304052 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29699358" @default.
- W2318304052 hasPublicationYear "2014" @default.
- W2318304052 type Work @default.
- W2318304052 sameAs 2318304052 @default.
- W2318304052 citedByCount "0" @default.
- W2318304052 crossrefType "journal-article" @default.
- W2318304052 hasAuthorship W2318304052A5010731876 @default.
- W2318304052 hasAuthorship W2318304052A5025888459 @default.
- W2318304052 hasAuthorship W2318304052A5088802067 @default.
- W2318304052 hasBestOaLocation W23183040521 @default.
- W2318304052 hasConcept C121608353 @default.
- W2318304052 hasConcept C126322002 @default.
- W2318304052 hasConcept C141071460 @default.
- W2318304052 hasConcept C2776760755 @default.
- W2318304052 hasConcept C2777138892 @default.
- W2318304052 hasConcept C2778260677 @default.
- W2318304052 hasConcept C2779134260 @default.
- W2318304052 hasConcept C2779174533 @default.
- W2318304052 hasConcept C2779280984 @default.
- W2318304052 hasConcept C2780955771 @default.
- W2318304052 hasConcept C530470458 @default.
- W2318304052 hasConcept C71924100 @default.
- W2318304052 hasConcept C90924648 @default.
- W2318304052 hasConceptScore W2318304052C121608353 @default.
- W2318304052 hasConceptScore W2318304052C126322002 @default.
- W2318304052 hasConceptScore W2318304052C141071460 @default.
- W2318304052 hasConceptScore W2318304052C2776760755 @default.
- W2318304052 hasConceptScore W2318304052C2777138892 @default.
- W2318304052 hasConceptScore W2318304052C2778260677 @default.
- W2318304052 hasConceptScore W2318304052C2779134260 @default.
- W2318304052 hasConceptScore W2318304052C2779174533 @default.
- W2318304052 hasConceptScore W2318304052C2779280984 @default.
- W2318304052 hasConceptScore W2318304052C2780955771 @default.
- W2318304052 hasConceptScore W2318304052C530470458 @default.
- W2318304052 hasConceptScore W2318304052C71924100 @default.
- W2318304052 hasConceptScore W2318304052C90924648 @default.
- W2318304052 hasIssue "2" @default.
- W2318304052 hasLocation W23183040521 @default.
- W2318304052 hasLocation W23183040522 @default.
- W2318304052 hasLocation W23183040523 @default.
- W2318304052 hasLocation W23183040524 @default.
- W2318304052 hasOpenAccess W2318304052 @default.
- W2318304052 hasPrimaryLocation W23183040521 @default.
- W2318304052 hasRelatedWork W1990312270 @default.
- W2318304052 hasRelatedWork W1997568406 @default.
- W2318304052 hasRelatedWork W2048740384 @default.
- W2318304052 hasRelatedWork W2120684581 @default.
- W2318304052 hasRelatedWork W2127424986 @default.
- W2318304052 hasRelatedWork W2386123288 @default.
- W2318304052 hasRelatedWork W2394491562 @default.
- W2318304052 hasRelatedWork W2547337719 @default.
- W2318304052 hasRelatedWork W3032508331 @default.
- W2318304052 hasRelatedWork W3145030480 @default.
- W2318304052 hasVolume "4" @default.
- W2318304052 isParatext "false" @default.
- W2318304052 isRetracted "false" @default.
- W2318304052 magId "2318304052" @default.
- W2318304052 workType "article" @default.